Instil Bio Total Long Term Liabilities 2020-2024 | TIL

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Instil Bio total long term liabilities from 2020 to 2024. Total long term liabilities can be defined as the sum of all non-current liabilities.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Instil Bio total long term liabilities from 2020 to 2024. Total long term liabilities can be defined as the sum of all non-current liabilities.

Related Stocks
Company Name	Market Cap
Amgen (AMGN)	$174.8B
Vertex Pharmaceuticals (VRTX)	$133.1B
Gilead Sciences (GILD)	$120.2B
Bristol Myers Squibb (BMY)	$109.8B
Regeneron Pharmaceuticals (REGN)	$91B
CSL (CSLLY)	$90.5B
GSK (GSK)	$75.2B
Alnylam Pharmaceuticals (ALNY)	$35.8B
Argenex SE (ARGX)	$35.6B
BioNTech SE (BNTX)	$26.3B
Biogen (BIIB)	$25.2B
Illumina (ILMN)	$24B
BeiGene (BGNE)	$20B
Moderna (MRNA)	$18B
Incyte (INCY)	$16.1B
Genmab (GMAB)	$15.3B
Vaxcyte (PCVX)	$13.3B
Insmed (INSM)	$13.2B
BioMarin Pharmaceutical (BMRN)	$12.8B
Bio-Techne Corp (TECH)	$12.1B
Sarepta Therapeutics (SRPT)	$11.6B
Exelixis (EXEL)	$10.4B
Revolution Medicines (RVMD)	$10.2B
QIAGEN (QGEN)	$10B
Intra-Cellular Therapies (ITCI)	$9.7B
Exact Sciences (EXAS)	$9.5B
Bio-Rad Laboratories (BIO.B)	$9.4B
Roivant Sciences (ROIV)	$8.8B
Repligen (RGEN)	$7.9B
Halozyme Therapeutics (HALO)	$7.8B